Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs ACTR-087/SEA-BCMA-combination-therapy (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 03 Jan 2019 According to an Unum Therapeutics media release, clinical data from multiple cohorts of the dose escalation phase and dose escalation phase progression anticipated in 2019.
    • 04 Dec 2018 Preliminary results of first two single subject cohorts presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Dec 2018 According to an Unum Therapeutics media release, preliminary results were presented at the American Society of Hematology (ASH) meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top